Chat with an Expert

iCell® Cardiac Progenitor Cells

Cardiac progenitor cells derived from human iPS cells, frozen

More Views

iCell® Cardiac Progenitor Cells

Cardiac progenitor cells derived from human iPS cells, frozen

5 x 106 cells
Catalog #70919
1,200 USD

Overview

Cardiac progenitor cells (CPCs) are able to proliferate and have the capacity to differentiate into mature cardiomyocytes. Thus, these cells are attractive targets in drug development applications for regenerative medicine programs focused on developing myocardial infarction and congestive heart failure treatments. They are also ideal for identifying and helping to avoid drug-mediated cardiac developmental toxicity problems across multiple programs, an application for which scientists require consistent and dependable access to human CPCs.

Derived from human induced pluripotent stem (iPS) cells, CDI’s iCell® Cardiac Progenitor Cells provide a robust, reproducible, and relevant source of cells to advance drug development and cardiac regenerative medicine programs. Benefits include:

- KDR+/PDGFR-α+/c-Kit- human CPC marker profile
- bFGF-mediated proliferation
- WNT inhibitor-mediated differentiation into cTNT+ cardiomyocytes
- High-throughput target and phenotypic-based screen compatibility

Certain products are only available in select territories. Please contact your local Sales Representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Subtype:
Frozen
Cell Type:
Cardiomyocytes, PSC-Derived
Species:
Human
Cell and Tissue Source:
Pluripotent Stem Cells

Scientific Resources

Educational Materials

(3)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Stem cells translational medicine 2016 FEB

Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.

Drowley L et al.

Abstract

Several progenitor cell populations have been reported to exist in hearts that play a role in cardiac turnover and/or repair. Despite the presence of cardiac stem and progenitor cells within the myocardium, functional repair of the heart after injury is inadequate. Identification of the signaling pathways involved in the expansion and differentiation of cardiac progenitor cells (CPCs) will broaden insight into the fundamental mechanisms playing a role in cardiac homeostasis and disease and might provide strategies for in vivo regenerative therapies. To understand and exploit cardiac ontogeny for drug discovery efforts, we developed an in vitro human induced pluripotent stem cell-derived CPC model system using a highly enriched population of KDR(pos)/CKIT(neg)/NKX2.5(pos) CPCs. Using this model system, these CPCs were capable of generating highly enriched cultures of cardiomyocytes under directed differentiation conditions. In order to facilitate the identification of pathways and targets involved in proliferation and differentiation of resident CPCs, we developed phenotypic screening assays. Screening paradigms for therapeutic applications require a robust, scalable, and consistent methodology. In the present study, we have demonstrated the suitability of these cells for medium to high-throughput screens to assess both proliferation and multilineage differentiation. Using this CPC model system and a small directed compound set, we identified activin-like kinase 5 (transforming growth factor-β type 1 receptor kinase) inhibitors as novel and potent inducers of human CPC differentiation to cardiomyocytes. Significance: Cardiac disease is a leading cause of morbidity and mortality, with no treatment available that can result in functional repair. This study demonstrates how differentiation of induced pluripotent stem cells can be used to identify and isolate cell populations of interest that can translate to the adult human heart. Two separate examples of phenotypic screens are discussed, demonstrating the value of this biologically relevant and reproducible technology. In addition, this assay system was able to identify novel and potent inducers of differentiation and proliferation of induced pluripotent stem cell-derived cardiac progenitor cells.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.